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Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.031The 2009 literature in cardiovascular surgery was character-
ized by several pivotal reports that will affect patient care
and future trial design for years to come. The purpose of our
annual review is to highlight key contributions in the field
that focus on strategies and outcomes in cardiovascular
surgery that practicing cardiovascular specialists will find
both informative and useful in their daily practice. Particular
emphasis this year was placed on articles that compare
surgical with nonsurgical alternative treatment strategies or
those that emphasize potential advances in specific surgical
strategies. Our goal as always is to provide readers of the
Journal with a succinct summary of specific studies orga-
nized around general categories, with pointed comments to
highlight special significance or methodological limitations
that cardiologists should consider in their pursuit of state-
of-the-art care for their patients.
Surgery for Valvular Heart Disease
Surgery for asymptomatic severe mitral valve regurgitation.
Long-term results in 161 patients who underwent early
surgery were compared with 286 patients who received
conventional medical follow-up for asymptomatic severe
mitral valve regurgitation in the setting of preserved left
ventricular function (1). The actuarial 7-year cardiac mor-
tality was 0% in the surgery group and 5  2% in the
conventional treatment group (p  0.0008), and actuarial
7-year event-free survival in 127 propensity score-matched
patients was 99 1% in the surgery group and 84 4% in the
conventional treatment group (p  0.007) (Fig. 1). In the
conventional treatment group, pulmonary hypertension (rel-
ative risk [RR]: 1.9, 95% confidence interval [CI]: 1.2 to
2.9, p  0.003), age (RR: 1.0, 95% CI: 1.1 to 1.0, p 
0.005), and effective regurgitant orifice area (RR: 2.1, 95%
CI: 1.1 to 3.8, p 0.02) were independent predictors of the
late development of surgical indications or congestive heart
failure.
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Manuscript received July 3, 2010, accepted November 25, 2010.In another study of 192 patients with asymptomatic
severe degenerative mitral valve regurgitation, overall, car-
diovascular, and event-free survival were evaluated in 67
patients managed by a “conservative approach” of waiting
for surgical indications to develop compared with 125
patients subjected to “early” surgery (2). Overall survival at
10 years was significantly better in patients undergoing early
surgery for severe mitral regurgitation (86% vs. 50%, p 
0.00001, log-rank test) (Fig. 2), and this remained true in
propensity subgroup analyses.
COMMENT. The timing of intervention on patients with
severe asymptomatic mitral regurgitation in the absence of
ventricular dysfunction or severe dilation remains contro-
versial. The American College of Cardiology/American
Heart Association (ACC/AHA) guidelines (3) recommend
early surgical intervention for patients with severe asymp-
tomatic mitral valve regurgitation and a high probability of
mitral valve repair. The results of these 2 studies reinforce
the conclusions of an earlier prospective study by Enriquez-
Sarano et al. (4) that had significant influence on the
ACC/AHA recommendation for early surgery: there is a
significant event rate (including mortality) in unoperated
asymptomatic patients with severe mitral valve regurgitation
subjected to conventional medical follow-up. An invited
editorial to the Kang et al. (1) article reinforced the
“unstated risk” of managing asymptomatic patients conser-
vatively, noting that some patients will be lost to follow-up
(occasionally because of death), whereas other patients will
not return until complications, including heart failure, occur
(5). Another invited editorial made the point that symptoms
were the trigger for later surgery in 94% of patients who
underwent conventional treatment in the Kang et al. (1)
series, whereas none were noted to have ventricular dysfunc-
tion during follow-up (raising the question of how carefully
echo follow-up actually was performed) (6). Both editorials
emphasized the other key to early surgery in the Kang et al.
(1) series: very low operative mortality (0%) and very high
repair rates (94%), reinforcing the importance of “reference
level” mitral surgery in asymptomatic patients.
Failure of guideline adherence in patients with severe
mitral regurgitation. At the University of Michigan, all
300 patients with moderate-to-severe mitral valve regurgi-
tation documented in the Echocardiographic Laboratory in
2005 were reviewed retrospectively to evaluate adherence to
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surgical intervention (7). Mitral surgery was performed in
59 (53%) of 112 patients with organic (nonischemic)
moderate-to-severe mitral valve regurgitation, whereas 1 or
more guideline indications for intervention were present in
39 (74%) of 53 unoperated patients. There were no signif-
icant differences in perioperative risks between operated and
unoperated groups with organic mitral disease, and during
follow-up, there were 12 cardiac and 2 unexplained deaths
in the unoperated group (Table 1).
COMMENT. This study from a leading mitral valve surgery
center documents a practice gap in terms of adherence to
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Figure 1
Event-Free Survival in Asymptomatic
Patients With Severe Degenerative Mitral
Regurgitation and Preserved Ventricular Function
Survival in patients with severe mitral regurgitation according to treatment
strategy. CONV  conservatively treated patients; OP  operated patients.
Modified and reprinted with permission from Kang et al. (1).
100
80
60
40
20
0
0 2 4 6 8 10
89 ± 4%
62 ± 7%
p < 0.0001
Early Surgery
Conservative approach
O
ve
ra
ll 
su
rv
iv
al
 (
%
)
Years after diagnosis
81   79    79     72       49       34
51   46    41     38       33       18
Figure 2 Event-Free Survival in Asymptomatic Patients With Se
Degenerative Mitral Regurgitation and No Associated
Survival in patients with severe mitral regurgitation, but without left ventricular dys
strategy. (A) Overall survival. (B) Cardiovascular (CV) event-free survival. The solid
patients treated conservatively. Modified and reprinted with permission from Montcurrent guidelines for intervention in patients with mitral
valve regurgitation. The findings re-enforce the need for
continuing education regarding the adoption of valve guide-
lines in daily practice and promoting the use of routine risk
assessment tools and multidisciplinary consultation in cer-
tain patient subgroups of patients with mitral valve
regurgitation.
Implications of pre-operative ventricular variables on
long-term outcome after mitral valve surgery. Recovery
of left ventricular function after surgical correction of
degenerative mitral valve regurgitation was evaluated in
1,063 patients who underwent surgery (mitral valve repair in
924 of 1,063 [87%]) between January 1980 and December
2000 (8). Patients had a greater likelihood of post-operative
ejection fraction 60% if the pre-operative ejection fraction
was65% (RR: 1.8, p 0.001) or if the left ventricular end
systolic diameter (LVESD) was 36 mm (RR: 2.0, p 
0.001).
In another study, a multicenter registry was investi-
gated to determine the effect of LVESD on survival in
739 patients with flail mitral leaflets (9). Under conser-
vative management, 10-year risk-adjusted cardiac death-
free survival was higher with an LVESD 40 mm versus
one of 40 mm or more (73  5% vs. 63  10%, p  0.001).
There was a persistence of risk-adjusted excess cardiac
mortality in patients with an LVESD of 40 mm of more
who underwent surgery (RR: 1.8, 95% CI: 1.0 to 3.5, p 
0.04) (Fig. 3).
COMMENT. These studies emphasize the importance of
careful assessment of left ventricular parameters in patients
with degenerative mitral valve regurgitation. Current ACC/
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of an LVESD of 40 mm or more or an ejection fraction of
60% or less in patients with chronic severe mitral valve
regurgitation (3). European guidelines (10) agree with the
ejection fraction threshold, but maintain the older ACC/
AHA surgical threshold of an LVESD of 45 mm or more
(11). Guidelines are likely to continue to move toward
earlier surgery and more liberal ventricular thresholds for
surgical intervention, before the onset of impairment of left
ventricular function.
Management of moderate mitral valve regurgitation in
patients undergoing aortic valve replacement. A retro-
spective review of 190 patients with moderate (grade 2)
functional mitral regurgitation left alone at the time of
aortic valve or root replacement found that in most in-
stances, the mitral regurgitation improved with correction of
the aortic valve pathological features alone (12) (Table 2).
Rationale for Not Permitting Mitral Surgery for STable 1 Rationale for Not Permitting Mitral
Rationale n (%)
Asymptomatic 9 (17%)
Stable LVEF, stable chambers 17 (32%)
MR improved on subsequent echocardiogram 6 (11%)
Comorbidities/risk 10 (19%)
Patient refused 4 (%)
Died before planned evaluation 1 (%)
MR unrecognized 4 (%)
MR ignored 2 (%)
Includes 4 cardiac deaths, 2 noncardiac deaths, and 1 death resulting fro
et al. (7). *There were 4 noncardiac deaths, 2 cardiac deaths, and 1 dea
LVEF  left ventricular ejection fraction; MR  mitral regurgitation.
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Figure 3 Adjusted Post-Operative Overall Survival According to
Adjusted post-operative survival according to left ventricular end-systolic diameter
Modified and reprinted with permission from Tribouilloy et al. (9).The long-term survival of 91 patients from this cohort was
similar to that of case matched patients without mitral
regurgitation undergoing aortic valve replacement (p  0.33).
COMMENT. These data support potentially leaving grade
2 or less mitral valve regurgitation untreated at the time of
aortic valve surgery for aortic stenosis or regurgitation. The
authors expressed an inclination to correct grade 3 or
ore mitral valve regurgitation surgically at the time of
ortic valve surgery, so we do not know from their study if
t is prudent to leave more than moderate mitral regurgita-
ion untreated in patients undergoing aortic valve surgery. It
ay well be that this question will be answered one day in
transcatheter aortic valve population with severe symp-
omatic aortic stenosis and grade 3 or more mitral valve
egurgitation deemed too high risk for surgical intervention
although current trials exclude such patients).
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regurgitation. Echocardiography was performed 12 months
fter surgery in 121 patients with moderate ischemic mitral
egurgitation who had undergone isolated coronary artery
ypass grafting (CABG): mitral regurgitation improved in
7 patients and was the same or worse in 64 patients (13).
re-operative predictors of improvement in mitral regurgi-
ation at 1 year of follow-up were greater area of viable
yocardium (5 segments) and absence of dyssynchrony
etween papillary muscles (p  0.001). There was clinical
correlation with the degree of residual mitral valve regurgi-
tation, because patients in whom regurgitation improved
had better survival and functional status (Fig. 4).
Mitral Regurgitation Grades After Isolated AorticValve Replacement in the Setting of Pre-OperativeAortic Stenos s a d Grade 2 Mitral Regurgitation
Table 2
Mitral Regurgita io Grades Af er Isolated Aortic
Valve Replacement in the Setting of Pre-Operative
Aortic Stenosis and Grade 2 Mitral Regurgitation
Mitral Regurgitation Grade n (%)
Discharge
1 23 (14%)
1 91 (57%)
2 42 (26%)
3 3 (2%)
4 0
Follow-up
1 16 (16%)
1 47 (47%)
2 34 (34%)
3 4 (4%)
4 0
Reprinted with permission from Wan et al. (12).
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Figure 4 Event-Free Survival in Patients With Moderate MR
Undergoing Coronary Artery Bypass Grafting
Kaplan-Meier event-free survival in patients with moderate mitral regurgitation
(MR) undergoing isolated coronary artery bypass grafting. The dashed red line
represents patients in whom MR was unchanged or worse at 12 months. The
solid blue line represents patients in whom MR improved or resolved. Modified
with permission from Penicka et al. (13).COMMENT. This contemporary study shows that moderate
mitral regurgitation often does not resolve after isolated
CABG, confirming prior work (14). The present study
provides clues into those patients in whom ischemic mitral
regurgitation may improve without concurrent mitral valve
surgery. An accompanying editorial emphasized that these
data remind us that the ventricle, rather than the valve,
should be our prime focus in targeting ischemic mitral
regurgitation (15). Pre-operative assessment of patients
with moderate ischemic mitral valve regurgitation probably
should include more detailed study of ventricular viability
and papillary muscle function, and results of these studies
should factor into the decision of whether to intervene on
the mitral valve in selected patients.
Outcome after aortic valve replacement in low-flow or
low-gradient aortic stenosis without contractile reserve.
Survival was examined in 81 consecutive patients with
symptomatic calcific low-flow or low-gradient aortic steno-
sis (valve area 1 cm2, left ventricular ejection fraction
40%, mean pressure gradient 40 mm Hg) without
emonstrable contractile reserve on dobutamine stress echo-
ardiography (16). Five-year survival was higher in patients
ndergoing aortic valve replacement versus medical man-
gement (54  7% vs. 13  7%, p  0.001), including 42
propensity-matched patients (65  11% vs. 11  7%, p 
0.02) (Fig. 5). Concomitant bypass surgery (p  0.007) and
mean pressure gradient of 20 mm Hg or less (p  0.03)
were predictive independently of operative mortality, which
was relatively high at 22% in the aortic valve replacement
group.
In another prospective single-center study, outcomes
were examined from 597 consecutive patients who under-
went aortic valve replacement for aortic stenosis, including
12% (n  73) with low ejection fraction low-gradient aortic
stenosis (defined as a left ventricular ejection fraction of
30% and mean transvalvular gradient of 35 mm Hg).
Medical management
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Figure 5 Prognostic Impact of AVR in Low-Flow or Low-Gradient
Aortic Stenosis Without Contractile Reserve
Kaplan-Meier survival in propensity-matched patients with low-flow or low-
gradient aortic stenosis without contractile reserve on dobutamine stress echo-
cardiography, according to whether they underwent aortic valve replacement
(AVR). Modified and reprinted with permission from Tribouilloy et al. (16).
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found to be an independent risk factor for mortality (17),
although it was a strong predictor of major post-operative
morbidity, including stroke (odds ratio [OR]: 4, 95% CI: 1
to 15, p  0.02), deep sternal wound infection (OR: 10,
95% CI: 2 to 46, p  0.01), and respiratory failure (OR: 4,
95% CI: 2 to 9, p  0.01).
COMMENT. Approximately one-third of patients meeting
current ACC/AHA Class I indications for aortic valve
replacement are denied surgery, and severe left ventricular
dysfunction is one of the most commonly cited reasons (18).
This European multicenter study is the largest to date to
examine the outcome of patients with low-flow or low-
gradient aortic stenosis without contractile reserve on
dobutamine stress echocardiography. Contractile reserve
documented on dobutamine stress echocardiography is
associated with lower operative risks in the setting of
low-flow or low-gradient aortic stenosis (19). These studies
emphasizes that aortic valve replacement still may represent
the best option, even in the absence of documented con-
tractile reserve, given the extremely poor survival with
conservative management. Other alternatives, including
heart transplantation or destination ventricular assist device
therapy, remain options in highly selected patients with
extensive coronary disease and myocardial scarring, or if the
mean pressure gradient is 20 mm Hg or less.
Patient prosthesis mismatch after aortic valve replacement.
Survival was analyzed in a retrospective review of 2,576
consecutive patients who survived to hospital discharge after
aortic valve replacement (20). Moderate patient prosthesis
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Figure 6 Impact of PPM on Survival in Patients With Left Vent
Survival after aortic valve replacement in patients with left ventricular ejection frac
red line  moderate PPM; green line  severe PPM. Modified and reprinted withmismatch, defined as an indexed effective orifice area be-
tween 0.85 and 0.65 cm2/m2, was identified in 31%; and
severe patient prosthesis mismatch, defined as 0.65 cm2/m2
or less, was present in 2%. After adjusting for risk factors,
severe patient prosthesis mismatch was found to predict
decreased late survival in patients younger than 70 years of
age, and moderate patient prosthesis mismatch was found to
predict decreased late survival in patients with reduced
pre-operative left ventricular ejection fraction 50%.
COMMENT. The impact of patient prosthesis mismatch on
clinical outcomes after aortic valve replacement remains
controversial. The group with patient prosthesis mismatch
in this study had a significantly higher proportion of
patients with almost all of the key baseline risk factors for
decreased survival, including more advanced age, obesity,
coronary artery disease, New York Heart Association func-
tional class III or IV status, hypertension, diabetes, renal
failure, and chronic lung disease, as well as significantly
longer cardiopulmonary bypass times. Although the unad-
justed survival curves suggest that a large decrease in survival
is associated with patient prosthesis mismatch, after risk
factors were controlled for, the only group in which mod-
erate prosthesis mismatch was an independent predictor of
decreased survival were patients with left ventricular dys-
function (Fig. 6), although the lower CI was close to 1.0.
Selection of prostheses to minimize the risk of patient
prosthesis mismatch in this scenario may have a role in
further improving operative mortality, but as pointed out by
Rahimtoola (21) in his later commentary, the very small
numbers of patients in each group by latter stages of
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with caution.
Overestimation of cardiac surgery risk by European System
for Cardiac Operative Risk Evaluation (EuroSCORE). A
single-center study examined operative mortality (observed vs.
predicted by additive or logistic EuroSCORE) in 1,545 con-
secutive patients undergoing isolated aortic valve replacement
over a 13-year period (22). The observed 30-day mortality
was 2.2% and was overestimated substantially by additive
(6.1%) and logistic (9.3%) EuroSCOREs. Higher-risk pa-
tients had 3.6% mortality, which also was overestimated by
additive (8.3%) and logistic (14.3%) EuroSCOREs. Al-
though EuroSCOREs successfully stratified patients into a
higher risk category for 30-day mortality, particularly in
more recently operated patients, it has become increasingly
uncalibrated to absolute risk (Fig. 7).
Another single-center study examined outcomes in 282
octogenarians undergoing isolated aortic valve replacement
for aortic stenosis to evaluate logistic EuroSCORE risk
stratification for operative mortality (23). Patient groups
were defined as low risk (logistic score 10%), moderate
risk (logistic score10% and20%), and high risk (logistic
score 20%); overall hospital mortality was 10.6% and was
not significantly discriminated between groups using logistic
EuroSCORE. Logistic EuroSCORE stratum, however, did
significantly predict midterm 5-year survival (low risk: 70%,
moderate risk: 53%, high risk: 38%, p  0.05).
In a third study, a predictive risk stratification model
limited to 3 independent factors (age, left ventricular ejec-
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Figure 7
Cumulative Sum Plot of Observed and Predicted 30-Day
Mortality After Aortic Valve Replacement for the Logistic
European System for Cardiac Operative Risk Evaluation
Plot of the cumulative sums of observed and predicted mortality after aortic
valve replacement. The solid diagonal line is the line of identity, representing
perfect agreement between predicted and observed mortality. Modified and
reprinted with permission from Osswald et al. (22).tion fraction, and creatinine level) was developed for elective
cardiac surgical procedures at a single institution, based on
analysis of 4,557 elective adult surgical patients (24). The
predictive accuracy of the abbreviated risk score was com-
pared with that of well-established more complex models,
including the additive and logistic EuroSCOREs in a
validation series of 4,091 patients, in which there were 105
deaths. The abbreviated risk score was shown to be accurate
in all subsets of the population with an area under the
receiver-operating characteristic curve always exceeding 0.8,
and it was the most accurate score for predicting operative
mortality (0.826) in elective patients undergoing isolated
CABG. All risk scores demonstrated good negative predic-
tive value (99%), but poor positive predictive value (8%).
COMMENT. EuroSCORE is a commonly used tool to assess
operative risks in patients undergoing cardiac surgery. It is
important to recognize that the data set supporting current
additive or logistic EuroSCORE systems was generated in
1995 across a spectrum of cardiac surgery patients, with a
vast majority of the study population undergoing coronary
artery bypass surgery and relatively few undergoing isolated
aortic valve replacement. Recognition of the limitations of
the current EuroSCORE models to predict operative out-
come in high-risk patients with aortic valve disease has led
to the adoption of the Society of Thoracic Surgeons (STS)
Predicted Risk of Mortality model as the standard for
current and future Food and Drug Administration trans-
catheter aortic valve replacement trials, which are intended
at this point to target high-risk patient populations with
severe symptomatic aortic valve stenosis. The STS Pre-
dicted Risk of Mortality model for isolated aortic valve
replacement was generated from a study population of
67,292 patients undergoing surgery between 2002 and 2006
(25). Current efforts are underway to recalibrate the Euro-
SCORE with a new patient cohort, and it should be empha-
sized that although the STS Predicted Risk ofMortality model
seems most accurately to predict mortality in high-risk patients
undergoing aortic valve replacement, no current risk stratifica-
tion system is calibrated to include all of the variables (such as
extreme frailty) that may be present in a current candidate
population for transcatheter valve therapy.
Despite sound methodology and calibration, the accu-
racy of large population risk prediction scores such as the
STS score and EuroSCORE rarely exceeds an area under
the receiver-operating characteristic curve of 0.75, and is
particularly poor in patients at the extremes of risk.
Intuitively, it may seem as though the greater the number
of patients and variables included, the better calibrated
each model will be. But including too many variables in
a risk stratification model may cause overfitting resulting
in a type I error, and a discrepancy in local practice such
as referral patterns or patient selection may reduce the
ability of an external model to discriminate within a local
population. Furthermore, restricting the risk factors in a
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the degree of user interpretation inherent in broader
models and also helps to reduce the chance of intercor-
relation between supposedly independent variables. In-
ternally developed risk stratification models, including a
smaller number of variables and applied to homogenous
patient sets, can be recalibrated annually to provide a
more accurate risk stratification at an institutional level.
Aortic prosthesis choice in younger patients. Between
1995 and 2003, 310 patients between the age of 55 and 70
years undergoing primary aortic valve replacement were
randomized to either a bileaflet mechanical valve versus a
second-generation bioprosthesis at a single institution (26).
There were no significant differences in baseline character-
istics between the 2 groups, and mean follow-up was 9  2
years. The study, which was powered to detect a 10%
difference in late mortality between the 2 arms, showed no
significant difference in operative mortality or morbidity,
survival (Fig. 8), or cumulative late complications, including
bleeding events, endocarditis, valve thrombosis, or non-
structural dysfunction according to whether patients had
undergone valve replacement with a mechanical or biopros-
thesis at 5, 10, or 13 years. The incidence of structural valve
degeneration and reoperation was higher in the biopros-
thetic group, with an escalating risk of valve failure starting
at 10 years after surgery and showing no reduction in risk
with time. The authors report linearized rates of valve
failure of 2% per patient-year (95% CI: 1.4 to 3) and of
reoperation of 2.3% per patient-year (95% CI: 1.5 to 3.1) for
bioprosthetic valves, compared with 0% and 0.6% per year
(95% CI: 0.2 to 1.1) for mechanical valves (p  0.001).
COMMENT. In patients older than 65 years of age, who
represent a steadily increasing proportion of patients under-
Figure 8 Survival in Middle-Aged Patients After AVR
According to Prosthesis Type
Survival after aortic valve replacement (AVR) in patients 55 to 70 years or age,
according to whether they received a mechanical AVR (dashed red line; MP) or
bioprosthesis (solid blue line; BP). Modified and reprinted with permission from
Stassano et al. (26).going valve surgery, reoperation rates with modern biopros-
theses are particularly low, and current guidelines suggest
bioprosthetic valves should be used routinely in these
patients (3,10). Valve choice in younger patients is more
controversial, and an accompanying editorial emphasizes
how this study contributes to literature dominated by
studies in older patients with valve models that since have
been superseded (27). Patient and physician preference has
shifted away from mechanical valves, even in patients
younger than the age threshold of current guidelines; this
may reflect increased awareness of the constant linearized
risk of thrombotic or hemorrhagic stroke associated with
mechanical valves, advances in surgical treatment of atrial
fibrillation, which consequently is no longer a strong relative
indication for a mechanical valve, and lifestyle choices.
Current data suggest that there is little or no survival
difference between mechanical and bioprosthetic valves.
The findings in this study confirm that patients undergoing
valve replacement with a mechanical valve can expect an
annual risk of major hemorrhagic or embolic event, includ-
ing stroke, of approximately 2% per year for life. Young
patients undergoing bioprosthetic valve replacement can
expect to start developing structural valve degeneration by
approximately 10 years and eventually will need reoperation.
Valve sparing versus valve replacement. The 30-day out-
comes of a multicenter registry of 151 patients undergoing
surgery for aortic root dilation resulting from Marfan’s
disease were analyzed according to whether patients under-
went aortic root replacement with a valved conduit (n 
46), including 39 mechanical and 7 bioprosthetic root
replacements, or using an aortic valve-sparing procedure
(n  105), which were all, with one exception, remodeling
ather than reimplantation procedures (28). Choice of
rocedure was entirely at the discretion of the surgeon.
atients who underwent valve-sparing surgery were signif-
cantly younger, had a lower incidence of acute type-A
issection, and were less likely to have severe aortic insuf-
ciency on presentation than patients in the root replace-
ent group; baseline characteristics otherwise were similar
etween the 2 surgical groups. There was no operative
ortality in either group and no difference in the very low
ates of major post-operative complications between groups.
rade of aortic insufficiency at discharge was mild or less in
ll patients.
Another study looked at long-term outcomes of valve-
paring root replacement in 103 patients with aortic dilation
esulting from Marfan’s disease, including 8 acute type-A
issections, reporting freedom from moderate or greater
ortic insufficiency of 92  4% at 10 years and 79  8% at
15 years (29). Operative mortality was 2%, with 10% of
patients requiring reoperation for bleeding.
COMMENT. Aortic root dilation is associated with signifi-
cantly increased risk of death from aneurysm rupture,
dissection, and aortic insufficiency, and it is an important
1432 Adams et al. JACC Vol. 57, No. 13, 2011
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are young, and composite mechanical root replacement
therefore is used frequently. As discussed above, in the
section on prosthesis choice, this carries a linear 2% annual
risk of major thromboembolic and hemorrhagic complica-
tions, including stroke. The analysis by Volguina et al. (28)
suggests that early outcomes of both valve-sparing and
valve-replacement techniques are comparable, although the
study was underpowered to detect the study primary end
point of a 20% difference in the composite end point of all
valve-related complications and provides no information on
late outcomes. The very low mortality rates reported in both
valve-sparing series reflects the substantial experience of the
surgeons in these single-surgeon series and has not been
replicated in national registry data.
Ross procedure. A meta-analysis of 39 series published
between 2000 and 2008, including more than 5,000 pa-
tients, was conducted to define better autograft durability,
morbidity, and mortality after the Ross procedure (30).
Mean follow-up in the 12 adult series, which contained
1479 patients, was 4 years (range: 1 to 7 years). Pooled early
mortality was 3% in adults, (95% CI: 1% to 7%), and the
rate of late mortality was 0.6% per year (95% CI: 0.3% to 1%
per year). The most common complication was structural
valve degeneration of the autograft, with a pooled rate of
autograft dysfunction of 1% per year, ranging from 0.1% to
2% per year, with a similar rate of right ventricular outflow
tract failure.
In a multicenter analysis of 1,335 patients who underwent
a Ross procedure between 1988 and 2008 with mean
follow-up of 6 years, pooled early mortality was 1%, and the
incidence of any mortality during follow-up was 2.6%. Low
rates of structural valve degeneration and reoperation rates
were observed (31).
COMMENT. The main limitations of the meta-analysis are
the inclusion of small series with relatively high mortality
and failure rates, and the very short length of follow-up. As
the accompanying editorial points out, the benchmark for
operative mortality for aortic valve replacement in young
adults is 1% (32), and other commentators have high-
lighted the authors’ conclusions regarding “durability limi-
tations” (21). The registry results, however, suggest that, in
experienced hands, the Ross procedure offers a durable
option for aortic valve replacement in adults with excellent
midterm survival and freedom from structural valve degen-
eration and reoperation.
Isolated tricuspid valve surgery: outcomes. Investigators
examined the midterm outcomes of 61 patients who under-
went isolated tricuspid valve surgery for severe tricuspid
regurgitation (33). Most patients had undergone prior
mitral valve surgery, including 10 who had prior tricuspid
valve repair. Eight patients underwent tricuspid valve
repair, and the remaining 53 patients underwent valve
replacement. Operative mortality was 10%, whereas me-dian hospital stay was 26 days. Of survivors, 39% had no
improvement in functional capacity at 6 months after
surgery. In multivariate analysis, pre-operative hemoglo-
bin and right ventricular end-systolic area were indepen-
dent determinants of outcome.
COMMENT. Surgery for severe tricuspid regurgitation
carries a high operative risk even in contemporary prac-
tice, and in many patients, correction may not result in
improved symptoms or survival. Operating on patients
before the right ventricle is severely dilated or before they
are anemic may improve outcomes. Because most of these
patients have undergone prior left-sided valve surgery,
these data support an aggressive strategy toward tricuspid
valve disease at the time of initial left-sided valve surgery.
Repair of incidental patent foramen ovale (PFO). Ret-
rospectively reviewed intraoperative transesophageal echo-
cardiogram data obtained from 13,093 patients undergoing
various cardiac surgical operations identified 2,277 (17%)
who had an incidental PFO diagnosed during surgery, of
which 639 (28%) underwent surgical repair (34). Patients
more likely to have their PFO repaired included females,
younger patients, those undergoing mitral or tricuspid valve
surgery, those with history of stroke or transient ischemic
attack, and those with less comorbidity. Some surgeons also
were more likely to repair incidental PFOs than others.
Propensity matching was used to compare outcomes in
patients in whom the PFO was repaired with those in whom
the PFO was present but not repaired; other than periop-
erative stroke, which was more prevalent in the repaired
group (odds ratio: 2.47, 95% CI: 1.02 to 6.00, p  0.04),
there was no difference in perioperative outcomes. There
was no difference in long-term survival when they compared
patients with PFO (regardless of whether repaired) with
those without a PFO; however, for patients with a PFO,
there was a tendency to better survival if the PFO was
repaired (p  0.12).
COMMENT. This study found no long-term survival benefit
to repairing an incidentally diagnosed PFO during cardiac
surgery and that there is a possibility that repair may
increase the incidence of perioperative stroke. Long-term
incidence of stroke was not reported; this would have been
useful to know, especially considering the tendency to
higher late mortality in the nonrepaired group and also that
stroke prevention is the principal basis for closure of
incidental PFOs. The study limitations include a long-study
period (1995 through 2006), where surgical and diagnostic
practices likely evolved, missing echocardiographic data on
most patients operated in the period (41,578 operations
were performed in the study period, but the authors could
obtain transesophageal echocardiograms before and after
surgery on only 34%), and low event rates, such that
estimates of effect were imprecise with wide CIs. Interest-
ingly, no biological explanation or hypothesis for their
observations was offered by the authors.
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Comparison of CABG and percutaneous coronary inter-
vention (PCI). SYNTAX TRIAL: DES VERSUS CABG FOR LEFT
AIN OR 3-VESSEL CAD. A total of 1,800 patients with
-vessel disease or left main CAD were assigned randomly
o undergo CABG or PCI with drug-eluting stents (Taxus
ES, Boston Scientific, Natick, Massachusetts) in a 1:1
atio (35). A noninferiority comparison of the 2 groups was
onducted with the primary end point of death from any
ause, stroke, myocardial infarction, or repeat revasculariza-
ion during the 12-month period after randomization. At 1
ear, the rates of major adverse cardiac or cerebrovascular
vents were significantly higher in the PCI group (17.8% vs.
2.4% for CABG, p  0.002) mostly because of an
increased rate of repeat revascularization (13.5% vs. 5.9%,
p  0.001). The rates of death and myocardial infarction
were similar between the 2 revascularization strategies at 12
months, whereas the stroke rate was significantly higher in
the CABG group (2.2% vs. 0.6% with PCI, p  0.003).
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Figure 9 Rates of Major Adverse Cardiac or Cerebrovascular E
PCI With Taxus and Cardiac Surgery Score and Treatm
Kaplan-Meier event-free survival in patients randomized to coronary artery bypass
according to their synergy between PCI with Taxus and cardiac surgery (SYNTAX) she authors concluded that CABG remains the standard of
are for patients with 3-vessel or left main CAD. A separate
mportant feature of this study was the definition of a
ynergy between PCI with taxus and cardiac surgery (SYN-
AX) score to predict outcomes based on the anatomical
haracteristics of coronary artery lesions (total occlusion,
ifurcation lesion, length of lesion 20 mm, and presence
f heavy calcifications). The rate of major adverse cardio-
ascular and cerebrovascular events was similar between the
groups in patients with low (0 to 22) and intermediate (23
o 32) SYNTAX scores; the rate of major adverse cardiac or
erebrovascular events and particularly the need for repeat
evascularization after PCI, however, was significantly ele-
ated in patients with high SYNTAX scores (33), indi-
ating very complex CAD (Fig. 9).
COMMENT. The SYNTAX trial is the first major random-
ized trial demonstrating that PCI with a drug-eluting stent
is less effective than CABG for preventing the 1-year
primary end point of major adverse cardiac or cerebrovas-
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disease, or both. This difference in outcomes mainly was the
result of the inclusion of repeat revascularization in the
primary end point. Perhaps the most significant finding of
the trial was the demonstration of a CAD burden scoring
system to define a high-risk subgroup (SYNTAX score:
33) in which CABG should be recommended strongly
versus multivessel or left main PCI, or both. Another
important finding of this study was the significantly higher
stroke rate in the CABG arm at 12 months. Unfortunately,
this study did not separate periprocedural from later stroke.
No information regarding stroke prophylaxis during the
CABG procedure was available. In addition, dual antiplate-
let therapy was prescribed only in the PCI arm, whereas
most CABG patients were treated with aspirin alone.
Likewise, only 74.5% of patients in the CABG group
received statin therapy, whereas in the PCI group, statin
therapy was instituted in 86.7% of patients (p  0.001).
An accompanying editorial emphasized the importance of
separating the diagnostic catheterization from the decision-
making process in complex cases to ensure a time for a
multidisciplinary heart team to review the data (36).
Sirolimus-eluting stent versus minimally invasive direct
coronary artery bypass grafting (MIDCAB) for proximal
left anterior descending artery (LAD) stenosis. A total of
130 patients were assigned randomly to either Sirolimus-
eluting stent (n 65) or MIDCAB (n 65) with off-pump
left internal mammary artery to LAD bypass surgery after a
left anterolateral minithoracotomy (37). The incidence of
major adverse cardiac events (MACE), such as cardiac
death, myocardial infarction, and the need for target vessel
revascularization, were compared at 1 year. Angiographic
follow-up within 12 months was performed in almost 90%
of patients in each group. The MACE rate was similar
between the 2 approaches and occurred in 5 patients (7.7%)
in each group (sirolimus-eluting stent: 1 myocardial infarction,
4 repeat revascularization procedures; MIDCAB: 5 myocardial
infarctions). The improvement in clinical symptoms and free-
dom from angina was similar between the 2 groups.
COMMENT. Previous studies comparing bare-metal stent-
ing and MIDCAB showed similar outcomes with respect to
Results of Post-Operative Coronary AngiographyTable 3 Results of Post-Operative Coronary Angiography
Variable Off-Pump Group On-Pum
At least 1 occluded graft, n of patients/total n (%) 250/685 (36.5) 197/6
Graft patency, no. of grafts/total n (%)
Overall 1,650/1,998 (82.6) 1,839/2,0
Saphenous vein 967/1,262 (76.6) 1,122/1,3
Left internal thoracic to left anterior descending
artery, FitzGibbon grade A
550/618 (89.0) 592/6A FitzGibbon grade A indicates excellent graft patency. Modified and reprinted with permission from Shro
CI  confidence interval.death and myocardial infarction, whereas the rate of repeat
revascularization was significantly higher in the PCI group.
This current trial showed that the need for repeat revascu-
larization is not eliminated with drug-eluting stents in
patients with isolated proximal LAD disease. The sirolimus-
eluting stent, however, was not inferior to MIDCAB surgery at
12 months with respect to freedom from MACE and was
performed with a lower rate of periprocedural complications
(the rate of myocardial infarction in the MIDCAB group in
this study was higher compared with that of previous
reports). Although additional studies with longer-term
follow-up are necessary, PCI with a drug-eluting stent
seems to be a safe revascularization strategy for proximal
LAD disease.
Comparison of off- and on-pump CABG: Veterans Affairs
Randomized On/Off Bypass trial. A total of 2,203 pa-
tients were assigned randomly for coronary revascularization
either to on- (n  1,099) or off-pump (n  1,104) CABG
procedures (38). The primary short-term composite end
point consisted of death or complications (reoperation, need
for mechanical support, cardiac arrest, stroke, or renal
failure) within 30 days after the operation. The primary
1-year composite end point was defined as death, repeat
revascularization procedure, and nonfatal myocardial infarc-
tion. Secondary end points included completeness of revas-
cularization, 1-year angiographic graft patency, neuropsy-
chologic outcomes, and the use of major resources. The
30-day composite outcome was not significantly different
between on- (5.6%) and off-pump (7%) CABG procedures
(p  0.19). The rate of composite outcome at 1 year was
igher in the off-pump group compared with the on-pump
roup (9.9% vs. 7.4%, p 0.04). The average number of grafts
er patient was marginally higher in the on-pump group
ompared with the off-pump group (3.0 1.0 vs. 2.9 0.9,
 0.002). The percentage of patients with fewer grafts
erformed than originally planned was significantly higher
n the off-pump group compared with the on-pump group
17.8% vs. 11%, p  0.001). The overall graft patency on
ngiography was lower in the off-pump group than in the
n-pump group (82.6% vs. 87.8%, p  0.01) (Table 3). The
uthors concluded that the off-pump surgical approach was
p
Absolute Percentage-Point Difference,
Off-Pump vs. On-Pump
(95% CI)
Relative Risk of Occlusion,
Off-Pump vs. On-Pump
(95% CI) p Value
.7) 7.8 (2.8 to 12.7) 1.27 (1.09 to 1.48) 0.002
.8) –5.2 (–7.4 to –3.0) 0.94 (0.92 to 0.97) 0.001
.8) –7.2 (–10.2 to –4.1) 0.91 (0.88 to 0.95) 0.001
.2) –4.2 (–7.4 to –1.1) 0.95 (0.92 to 0.99) 0.01p Grou
86 (28
95 (87
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35 (93yer et al. (38).
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The neuropsychological outcomes and use of major resources
were similar between on- and off-pump approaches.
COMMENT. The Veterans Affairs Randomized On/Off By-
pass trial was a large randomized, controlled study compar-
ing on- and off-pump CABG procedures. This study
showed similar early mortality and morbidities between the
2 groups and confirmed the findings of previous randomized
studies that have included smaller numbers of patients. A
major finding of this trial was that the mean number of
grafts per patient was significantly lower in the off-pump
group compared with the on-pump group. Similarly, the
angiographic graft patency rate was lower in the off-pump
group. These 2 findings are in opposition with data from
experienced centers in off-pump procedures, which have
reported similar numbers of grafts and long-term patency
between the 2 approaches. One potential explanation for
these findings may be the limited experience of certain
Veterans Affairs Randomized On/Off Bypass surgeons in
off-pump procedures (experience with only 20 off-pump
cases was required to qualify as a trial surgeon). Another
limitation of this study is that participating patients were
almost exclusively male without severe comorbidity. Addi-
tional studies are necessary to investigate the potential
benefit of off-pump CABG in female patients and sicker
patients. Similar neurocognitive outcomes between the 2
procedures is now well documented and further confirmed
by this study. An accompanying editorial points out that
off-pump techniques likely will remain reserved for selected
patients and skilled surgeon advocates (39).
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Figure 10 Event-Free Survival After Coronary Artery Bypass Gra
Adjusted Kaplan-Meier event-free survival in patients after coronary artery bypass g
via either an endoscopic or open approach. Modified and reprinted with permissioComparison of endoscopic versus open vein graft harvesting
in CABG. The outcomes of 3,000 patients undergoing
CABG with either endoscopic vein harvesting (n  1,753)
r harvesting under direct vision (n  1,247) was reviewed
n a secondary analysis of the PREVENT IV (Project of
x-Vivo Vein Graft Engineering via Transfection IV) trial
40). The technique of vein harvesting was not randomized
nd was left to surgeon discretion; baseline demographic
haracteristics were similar between the 2 groups. Late
linical outcomes, including death, myocardial infarction,
nd repeat revascularization, were reported. Angiographic
tudies at 12 to 18 months showed a higher rate of vein graft
ailure in the endoscopic group compared with the open
roup (46.7% vs. 38%, p  0.001). At 3 years, endoscopic
ein harvesting was associated with higher rates of death,
yocardial infarction, or repeat revascularization (20.2% vs.
7.4%, p  0.04) (Fig. 10).
COMMENT. Endoscopic vein harvesting in patients under-
going CABG has become popular during the last decade
because of fewer wound complications, better cosmesis,
decreased post-operative pain, and overall improved patient
satisfaction. Previous studies comparing endoscopic versus
open vein harvesting mainly have focused on early outcomes
and have reported similar results between these 2 tech-
niques. This secondary analysis from the PREVENT IV
trial showed that endoscopic vein graft harvesting may be
associated independently with vein graft failure at 1 year and
major adverse clinical events at 3 years. Confounding factors
that were not accounted for in this study include on- versus
off-pump techniques, the quality of the vein grafts, the
quality of the distal targets, or the experience of endoscopic
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the PREVENT IV trial compared with most previous
reports.
The authors emphasize the need for mechanistic studies
to identify the potential injury mechanisms associated with
endoscopic vein harvesting (40). One such study comparing
endoscopic and open vein harvesting found that the endo-
scopic technique was associated with saphenous vein endo-
thelial damage, reduced nitric oxide production, and de-
creased calcium mobilization in response to bradykinin (41).
These alterations in saphenous vein structure and function
associated with endoscopic harvesting potentially may ex-
plain the worse outcomes reported in this secondary analysis
of the PREVENT IV trial. A randomized trial is warranted
to clarify further the potential short-term benefits versus
long-term risks of endoscopic vein harvesting in CABG
patients.
Intraoperative completion angiography after CABG and
hybrid revascularization. The outcomes of 366 consecu-
tive patients who underwent CABG with (n  112) or
without (n  254) concomitant PCI during the same
procedure (hybrid) in a single institution were reviewed. All
patients underwent a completion angiography before chest
closure. The hybrid CABG and PCI procedure was planned
in 67 patients (60%), whereas 45 patients (40%) underwent
an unplanned hybrid procedure based on intraoperative
findings. The indications for planned hybrid procedures
were: minimizing surgical risk (n 32), poor conduits (n 3),
ungraftable vessels (n  29), or stenting of the left subcla-
vian artery (n  3). The indications for unplanned hybrid
were: graft defects (n  43), poor conduits (n  1), or
ungraftable vessels (n  2).
Clinical outcomes were similar between the 2 groups.
The operative mortality was 2.6% (n  3) in the hybrid
group versus 1.5% (n  4) in the conventional CABG
group (p  0.33). The administration of higher dose
clopidogrel in the hybrid group was not associated with
increased post-operative chest tube output. In addition,
the rate of reoperation for bleeding was not different
between the groups. One patient in the hybrid group had
acute post-operative in-stent thrombosis that was asso-
ciated with a fatal outcome. Operating room time and
costs were higher in the hybrid group. Completion
angiography showed 12% of grafts (97 of 796) to have
important defects. These defects were as follows: conduit
defects (n  54, 6.8%), anastomotic defects (n  30, 3.7%),
and target vessel errors (n  13, 1.6%). Defects were repaired
withminor adjustment of the graft (n 22, 3%), with unplanned
PCI (n  48, 6%), or with surgical revision (n  27, 3.4%).
COMMENT. An increasing number of surgeons use technol-
ogies such as the transit time flow meter to assess intraop-
erative graft patency, particularly in patients undergoing
off-pump CABG procedures. This study suggests that
intraoperative completion angiography may be a valuabletool that can provide significant information with major
clinical implications. The Vanderbilt group pioneered the
concept of hybrid operating strategies in which a CABG or
valve operation is completed by a concomitant PCI proce-
dure. Although this 1-stop hybrid concept may be useful in
a select group of patients, additional studies are necessary to
determine further its role in daily clinical practice.
Pre-operative clopidogrel administration in patients with
acute coronary syndromes undergoing CABG. The out-
come of 1,520 patients with non–ST-segment elevation
acute coronary syndromes requiring CABG was reviewed in
a subgroup analysis of the ACUITY (Acute Catheterization
and Urgent Intervention Triage strategY) trial (42). Out-
comes in clopidogrel-exposed patients (n  773, 51%) were
ompared with those of patients not exposed to this agent
efore surgery (n  747, 49%). Baseline patient character-
stics were similar between the 2 groups. Of the 773 patients
xposed to clopidogrel, 73 received it before hospitalization,
57 received it before hospitalization and in the hospital,
nd 543 patients received clopidogrel in the hospital only.
f these 773 patients, 524 (67.8%) patients underwent
ABG fewer than 5 days after the last clopidogrel dose and
49 (32.2%) patients underwent CABG more than 5 days
fter the last clopidogrel dose. Clopidogrel-exposed patients
ad fewer composite ischemic events defined as death,
yocardial infarction, or unplanned revascularization at 30
ays (12.7% vs. 17.3%, p  0.01). In multivariate analysis,
re-operative clopidogrel administration was an indepen-
ent predictor of reduced 30-day composite ischemia (odds
atio: 0.67, p  0.001). The rates of non–CABG-related
ajor bleeding (3.4% vs. 3.2%, p 0.87), blood transfusion
38.4% vs. 38.4%, p  1), and reoperation for bleeding
1.3% vs. 1.3%, p 0.94) were similar in those patients who
id and did not receive clopidogrel before CABG. In the
ohort of clopidogrel-exposed patients, the rate of ischemia
nd bleeding was slightly higher in the group of patients
ho underwent CABG within 5 days after the discontinu-
tion of the treatment.
COMMENT. This subgroup analysis from the ACUITY trial
showed that upstream administration of clopidogrel in
patients with non–ST-segment elevation acute coronary
syndromes requiring urgent cardiac catheterization and
referred for CABG is beneficial and is associated with a
significant reduction in post-operative ischemic events.
Moreover, this clinical benefit was not compromised by an
increased rate of major bleeding or blood transfusion in the
clopidogrel-exposed group of patients. The latter events
occurred, however, at a modestly higher rate in the group of
patients who underwent CABG fewer than 5 days after the
discontinuation of this medication. An accompanying edi-
torial emphasized that these findings support the current
ACC/AHA guidelines for upstream clopidogrel adminis-
tration in all non–ST-segment elevation acute coronary
syndromes patients and ACC/AHA and Society of Tho-
1437JACC Vol. 57, No. 13, 2011 Adams et al.
March 29, 2011:1425–44 Year in Cardiovascular Surgeryracic Surgeons guidelines for a 5-day waiting period after
the termination of clopidogrel before proceeding with
CABG unless there is an urgent or emergent indication for
the procedure (43). Additional studies are required to
understand better this protective effect of pre-operative
clopidogrel administration.
Effect of prior PCI on the outcome of CABG. The
outcomes of 29,928 patients undergoing primary CABG
between 2000 and 2005 in 8 cardiac centers were reviewed
(44). Patients were divided into 3 groups: no previous PCI
(n 25,752, 86%), 1 previous PCI (n 3,078, 10.3%), and
2 or more previous PCIs (n  1,098, 3.7%). Risk-adjusted
multivariate analysis showed that 2 or more previous PCIs
were associated with a significant increase in hospital
mortality (OR: 2.0, p  0.0005) and major adverse cardiac
events (OR: 1.5, p  0.01).
In another retrospective study, the outcomes of 1,758
diabetic patients who underwent primary CABG between
2001 and 2006 were analyzed (no previous PCI: n  1,537,
87.5%; previous PCI: n  221, 12.5%) (45). After risk
adjustment, patients with a history of PCI had an increased
operative mortality (OR: 4.0), rate of perioperative MACE
(OR: 2.7), and decreased age-adjusted survival at 2 years
(93.4% vs. 87.4%, p  0.01).
COMMENT. There has long been a feeling among surgeons
that previous PCI may complicate CABG procedures. The
results of these studies are in agreement with some earlier
smaller studies. Multiple attempts at reintervention with
PCI, particularly in diabetic patients, probably should be
avoided in patients who are reasonable CABG candidates.
Although there are several possible hypotheses to explain
the observations, such as the existence of a more progressive
form of the atherosclerotic disease in patients with prior
PCI undergoing CABG, post-stenting inflammatory re-
sponse with endothelial dysfunction, or distal implantation
of a bypass graft forced by the presence of multiple proximal
stents, the mechanism(s) by which prior PCI compromises
the outcomes of CABG remain undetermined. An invited
editorial questioned if these results should dampen enthu-
siasm toward hybrid approaches and reinforced that patients
requiring complex revascularization may be better served by
primary CABG (46).
Surgery for Advanced Heart Failure
Left ventricular assist devices (LVADs): extended support.
As a follow-up study to the 2007 report that presented
6-month outcomes of patients bridged to cardiac transplan-
tation with the HeartMate II (Thoratec Corporation, Pleas-
anton, California) continuous LVAD (47), the HeartMate
II investigators report on the 18-month follow-up of the
281 patients enlisted in this multicenter, prospective study
(48). All patients received a HeartMate II LVAD, which is
a second-generation axial flow pump, as part of a Food and
Drug Administration pre-approval study. The investigatorsfound that at 18 months, 56% of patients had been
transplanted and 21% remained alive and on device support,
whereas 20% had died while on LVAD support (in the
remainder, the heart had recovered and the LVAD had
been explanted). Considering only patients who remained
on LVAD support (censoring patients at transplantation or
explantation), the actuarial patient survival at 18 months
was 72%, whereas the freedom from major device malfunc-
tion was 92%.
COMMENT. Because two-thirds of the patients underwent
transplantation or died within 9 months of device implan-
tation, a minority of patients actually required extended
support. In this subgroup, excellent device durability asso-
ciated with reasonable morbidity and good survival was
demonstrated.
LVADs: continuous-flow versus pulsatile-flow devices.
Another study published by the HeartMate II investigators
provides better insight into longer-term efficacy of contin-
uous flow LVADs. In this study started in 2005 (49), the
investigators evaluated the role of the HeartMate II LVAD
as definitive or “destination” therapy for advanced heart
failure in patients ineligible for transplantation. They ran-
domized 200 patients to receive the then approved pulsatile-
flow device for destination therapy (HeartMate XVE, Tho-
ratec Corporation, Pleasanton, California) (n  66) or the
investigational continuous-flow HeartMate II device (n 
134). The primary composite end point of survival without
disabling stroke and reoperation for device malfunction at 2
years was reached by 46% of patients in the continuous-flow
LVAD group compared with 11% in the pulsatile-flow
group (p  0.001). The actuarial 2-year patient survival was
substantially better in those who received continuous flow
LVADs (58% vs. 24% in the pulsatile group, p  0.008)
(Fig. 11).
COMMENT. This rare randomized trial of 2 surgical thera-
pies demonstrates the superiority of the second-generation
continuous-flow LVADs over pulsatile-flow LVADs, with
substantial reduction in risk of death and device failure at 2
years. Secondary analysis also showed a reduction in risk of
device failure, device infection, right ventricular failure, and
renal failure—all major limitations to extended use of
mechanical circulatory support. An accompanying editorial
highlighted some limitations of the study, including absence
of information on screened but not enrolled patients and the
possibility of bias in patient care and study reporting because
of lack of blinding (50). Also, this cohort represented a low-
to medium-risk cohort of patients requiring destination
therapy that may not be typical of those seen in routine
practice. Nevertheless, this study has opened a new era in
the use of continuous flow LVADs as permanent destina-
tion therapy for patients with advanced heart failure; the
results of this study have rendered obsolete the use of
pulsatile LVADs for long-term support. The particularly
poor results in the pulsatile group raise questions as to
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new ventricular assist device technology.
LVADs: use in less sick heart failure patients. LVADs
enerally have been reserved as a bridge to cardiac transplan-
ation and for use as destination therapy in patients with stage
heart failure not suitable for transplantation. LVADs are
sed as cardiac replacement therapy in this context. A novel
pproach is to use LVADs to provide partial ventricular
upport in severely symptomatic heart failure patients who do
ot yet meet hemodynamic criteria for complete cardiac
eplacement therapy. In a prospective feasibility study, the
ynergy Pocket Micro-pump device (CircuLite, Inc., Saddle
rook, New Jersey) was implanted in 17 patients with ad-
anced heart failure, of whom 15 required repeated hospital-
zations for decompensations but were not receiving intrave-
ous inotropic therapy (51). The Synergy device is a new-
eneration micropump, approximately the size of an AA
attery, that is implanted minimally invasively in the right
nfraclavicular fossa with an outflow connected to the subcla-
ian artery and an inflow placed into the left atrium through a
mall right thoracotomy without cardiopulmonary bypass. The
ump generates an output of only 2.5 to 3 l/min (as opposed to
onventional LVADs, which can provide up to 10 l flow/min),
ut the theory is that this would supplement, rather than
eplace, the native heart output and that the cumulative output
ould be sufficient to reverse symptoms. The authors indeed
ound an increase in the mean cardiac output from 3.8 l/min
efore surgery to 6.3 l/min (p  0.0001) daily after surgery,
and in 9 patients who had cardiac catheterization (4 to 19
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Figure 11 Survival After LVAD Implantation According to Devic
Kaplan-Meier survival of patients who received either a continuous- or pulsatile-flow
Pulsatile-flow LVADs were replaced with continuous-flow LVADs in 31% of patients.weeks after implantation), there remained evidence of hemo-dynamic improvement (Fig. 12). Of the 17 patients, there were
3 deaths, 1 reoperation to place a biventricular assist device, and
8 pump exchanges for pump thrombus.
COMMENT. This study demonstrates that in less sick heart
failure patients, it is possible to improve hemodynamics by
placing a micropump that flows only 2.5 to 3 l/min.
Although hemodynamics were enhanced, the adverse event
rate was high, and patients were not supported long enough
to evaluate for sustained improvement in quality of life with
this approach (median duration of support was 81 days; all
but 4 of the 13 survivors on device had undergone trans-
plantation by the time of the report). Pump thrombosis is a
concern, but authors report that modifications to device
design and higher-target international normalized ratio
have reduced its frequency. Future study in New York Heart
Association functional class III patients not requiring car-
diac transplantation should allow longer periods of support
to determine the clinical outcomes of partial ventricular
support compared with medical therapy.
Surgical ventricular reconstruction: the STICH (Surgical
Treatment for Ischemic Heart Failure) trial. The STICH
investigators published the results of their hypothesis 2 arm,
which included 1,000 patients with left ventricular ejection
fraction 35% and anterior wall left ventricular dysfunction
randomized to CABG alone or CABG with surgical ven-
tricular reconstruction (SVR) (52). No difference was found
between the 2 groups in terms of the primary outcome
(death from any cause or hospitalization for cardiac cause)
12 18 24
since Randomization
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March 29, 2011:1425–44 Year in Cardiovascular Surgeryup to 5 years (Fig. 13). An economic analysis of the same
cohort published separately did not show any difference in
health-related quality of life using both disease-specific and
generic tools and also found that the hospital costs were
$14,500 more in the SVR group (53).
COMMENT. This study, which suggested that SVR does not
lead to improvement in survival or reduction in hospitaliza-
tions or symptoms compared with CABG alone, has had a
divided response among surgeons and cardiologists. An
accompanying editorial concluded that the routine use of
SVR cannot be justified (54), whereas another editorial
suggested the lack of efficacy of SVR may be the result of
the disturbance of the 3-dimensional architecture of the
ventricle with deleterious effect on both systolic and dia-
stolic function (55). Some experts in the surgical commu-
nity, however, are very critical of the trial design and
question the robustness of the study conclusions. Most of
these limitations are detailed in a commentary by Buckberg
and Athanasuleas (56). The strongest criticism arises from
the quality of the surgical procedures performed in the
study. The STICH investigators, based on prior data,
stipulated that SVR should achieve at least a 30% reduction
in ventricular volume, but actual measurement of volumes in
the 161 SVR patients who underwent post-operative imag-
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Figure 12 Hemodynamic Changes Associated With Partial Ven
Pulmonary artery (PA) systolic pressure and cardiac index before insertion of a mic
10  6 weeks after insertion. Red lines represent individual patients. Blue lines aing showed that the mean volume reduction was 19%,implying that many patients did not have adequate ventric-
ular repair. Furthermore, although SVR is reserved for
patients with prior myocardial infarction with regional scar,
13% of patients in the trial had no prior myocardial
infarction. Imaging data requirements on enrollment and
follow-up also were not met for most patients, making it
impossible to define with certainty the pre- and post-
operative ventricular geometry and volumes, such that
patients who did not need SVR (because they had ventric-
ular volumes below the required threshold for SVR) may
have been included in the trial. Two-thirds of patients did
not undergo a volume measurement after surgery. The
reality, therefore, is that the patients included in the trial
may not necessarily reflect the true target for SVR therapy,
and a substantial proportion of patients in the SVR group
did not receive the trial-defined intervention (ventricular
repair to achieve at least 30% volume reduction). Buckberg
and Athanasuleas argue that “the wrong operation, using
the wrong volume measurements, was done on the wrong
patients resulting in the wrong conclusions” and called for
retraction of the study.
Surgical ventricular reconstruction: superior results with
mitral annuloplasty versus replacement. Long-term out-
comes were reported for 76 patients with ischemic cardio-
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mitral valve regurgitation (57). Of note (see STICH trial in
the previous text), a mean ventricular volume reduction of
40% was achieved in these patients. The 5-year survival of
the cohort was 68% and was superior in the subgroup
undergoing valve repair (Fig. 14).
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in Patients With Left Ventricular Ejection Fraction <
Kaplan-Meier estimates of the probability of major adverse cardiac events or deat
permission from Jones et al. (52). CABG  coronary artery bypass grafting; SVR 
Figure 14
Survival in Patients With End-Stage
Ischemic Cardiomyopathy and Mitral
Regurgitation Treated by MVRep or MVR
Five-year survival following mitral valve repair (MVRep) or mitral valve replace-
ment (MVR) for mitral regurgitation in patients undergoing surgical ventricular
restoration for end-stage ischemic cardiomyopathy. Modified and reprinted with
permission from Suma et al. (57).COMMENT. Excellent long-term outcomes are achievable
with SVR, where 40% volume reduction was achieved.
With mitral insufficiency, valve annuloplasty has substan-
tially better results than replacement. This may reflect a
higher risk associated with replacement, bias introduced by
more advanced ventricular disease in the replacement co-
hort, or both.
Heart transplantation: results with alternate heart listing.
Alternate heart lists increasingly are prevalent. In this
strategy, high-risk patients who ordinarily are not candi-
dates for transplantation, such as elderly patients, are listed
for transplantation, but undergo transplantation only with
marginal donor organs, which usually would not meet
criteria for use for transplantation. This study explored the
degree to which matching marginal donors with high-risk
recipients compromises post-transplant outcomes by ana-
lyzing 13,024 transplants performed in the United States
between 1999 and 2005 (58). They found that the results of
transplantation were substantially worse when high-risk
recipients were paired with marginal donors (5-year sur-
vival: 51.4%) compared with standard donors receiving
standard hearts (5-year survival, 75%) (Fig. 15).
COMMENT. Expectedly worse survival is seen when mar-
ginal donor hearts are used on alternate list recipients.
However, a median survival of 5 years is a substantial
improvement on a median survival of 6 to 12 months that
many of these patients otherwise would face without trans-
plantation. The higher 1-year mortality may lead to reluc-
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quality, unless outcomes in this subgroup are considered
separately in the future.
Miscellaneous
Atrial fibrillation (AF). Continuous heart rhythm surveil-
lance was carried out for 2 years after surgical atrial ablation
in 45 cardiac surgery patients with a pre-operative history of
AF using an implantable cardiac rhythm monitor (Reveal
XT 9529, Medtronic, Inc., Minneapolis, Minnesota) (59).
Two patients underwent lone atrial ablation, and 43 under-
went ablation concomitantly with other cardiac surgical
procedures: high-intensity ultrasound was used in 33 pa-
tients, and cryothermy was used in 12 patients. All patients
had pulmonary vein isolation, and in patients with persistent
AF, an additional ablation line to the left atrial isthmus was
created. Complete sinus rhythm with no AF burden was
achieved in 43% of patients, whereas approximately one-
third of patients were in AF on average for between 1 to 8
h/day, and 31% had an average daily burden of AF of more
than 8 h. In comparison, the sensitivity of conventional
interval Holter monitoring performed at 3-month intervals
was just 60%, only identifying recurrence of AF when it was
present for more than 17  8 h/day. All except 4 patients
ere asymptomatic.
COMMENT. “Snapshot” assessment of cardiac rhythm using
interval electrocardiograms, 24-h Holter recording, or
symptom-driven monitoring overestimates the success rates
of conversion from AF. Implantable wireless devices pro-
grammed automatically to store data quantifying AF burden
Figure 15 Survival After Cardiac Transplantation
ALT  alternate list transplant (high-risk recipient and marginal donor;
black line); HR:SD  high-risk recipient and standard donor (green line);
SR:MD  standard recipient and marginal donor (red line); STD  standard
recipient and standard donor (blue line). Modified and reprinted with per-
mission from Russo et al. (58).provide continuous rhythm surveillance and seem to docu-ment significantly more episodes of recurrent AF, particu-
larly in a minority of patients who have late recurrent AF.
Cardiopulmonary bypass (CPB), vasoplegia, and micro-
vascular dysfunction. The association between hypoten-
sion immediately after institution of CPB and the incidence
of post-bypass vasoplegia was analyzed retrospectively in
2,823 patients undergoing adult cardiac surgery (60). The
incidence of vasoplegia after starting CPB (defined as a
requirement for near maximal vasopressor support) was 20%
and was closely correlated with a decline in mean arterial
pressure of20% from baseline lasting for more than 2 min
within the first 5 min of CPB. Three main hemodynamic
patterns were observed after starting bypass: an early,
dramatic fall in mean arterial pressure responsive to vaso-
constrictors; a more gradual decline that persisted despite
pharmacological intervention; and an intermediate group
with gradual decline that responded well to pharmacother-
apy. Vasoplegia after starting CPB was found to be a strong,
independent predictor of prolonged hospital stay and oper-
ative mortality (OR: 2.62, 95% CI: 2.05 to 3.36, p 0.001).
Independent risk factors for vasoplegia identified in this
study included pre-operative beta-blocker and angiotensin-
converting enzyme-inhibitor use, valve surgery, reopera-
tion, increasing EuroSCORE, pre-bypass aprotinin, and
hypotension.
In another study, the deleterious effects of bypass on
tissue perfusion were examined at the microvascular level by
quantifying sublingual capillary blood flow in patients dur-
ing on- and off-pump cardiac surgery, and the results were
compared with those of patients undergoing general anes-
thesia for noncardiac surgery (61). In all 3 patient groups,
microvascular dysfunction resulted in marked heterogeneity
of perfusion after induction, which was significantly worse
in patients undergoing cardiac surgery compared with major
noncardiac surgery, persisted for more than 24 h after
surgery, and was only slighted exacerbated by cardiopulmo-
nary bypass compared with off-pump cardiac surgery.
COMMENT. Cardiopulmonary bypass likely causes vasople-
gia through 3 interrelated mechanisms (61). First, patients
may exhibit a hypersensitivity response causing a persistent
proinflammatory state: in these patients, the resultant hy-
potension may be addressed partially by use of vasoconstric-
tors. Second, bypass may result in widespread endothelial
dysfunction in some patients, causing hypotension that is
refractory to vasopressors. Third, the institution of bypass
may contribute to mechanical dysfunction of the vascular
system resulting from loss of pulsatile flow and hemodilu-
tion: the resultant hypotension may be compensated for to
some extent by use of vasopressors and resolves on cessation
of bypass.
Most centers already routinely withhold angiotensin con-
verting enzyme-inhibitors for 24 h before cardiac surgery to
reduce the risk of post-bypass vasoplegia, and there may be
a case for assessing the risks and benefits of a similar strategy
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major impact of endothelial dysfunction on outcomes after
cardiac surgery and the multifactorial cause and pathogen-
esis of post-operative malperfusion states. The finding that
significant endothelial dysfunction and tissue malperfusion
is associated with off-pump cardiac surgery, with a relatively
small increment resulting from cardiopulmonary bypass,
may partly explain the similarity in morbidity and mortality
observed between the 2 techniques in randomized studies.
Pre-operative anemia and bleeding. The role of pre-
operative anemia (defined as hemoglobin12 g/dl in men and
11 g/dl in women) as a predictor of early and late mortality
fter CABG was analyzed by comparing outcomes in
0,025 patients who underwent CABG at a single center
etween 1998 and 2007 with a matched population cohort
62). The incidence of pre-operative anemia was 16% (n 
,608): lower hemoglobin was associated with diabetes
ellitus, chronic obstructive airways disease, peripheral
ascular disease, low left ventricular ejection fraction, renal
ysfunction, prior cardiac surgery, emergency surgery, in-
raoperative transfusion, and need for intra-aortic balloon
upport. Patients with normal hemoglobin levels were more
ikely to be younger men. Multivariate logistic regression
nalysis showed that low hemoglobin was an independent
isk factor for late mortality (hazard ratio: 1.61, 95% CI: 1.4 to
.8, p  0.0001), both as a continuous variable and as a
ichotomous variable (anemia), along with age and re-
xploration for any reason. Post-operative survival of pa-
ients with normal pre-operative hemoglobin levels was
ound to be better than that of an age-matched population.
Recombinant factor VIIa is approved by the Food and
rug Administration for the treatment of perioperative
leeding in patients with coagulopathies such as hemo-
hilia, although concern about thrombotic complications
imits the liberal use of the drug in the setting of cardiac
urgery. In a multicenter trial, 179 patients who met a
respecified bleeding rate after cardiac surgery were ran-
omized to placebo, low-dose factor VIIa (40 g/kg), or
igh-dose factor VIIa (80 g/kg) (63). Significantly fewer
atients in the 2 groups receiving factor VIIa underwent
eoperation or required allogeneic transfusions, and the
ncrease observed in a composite end point of adverse events
including death, myocardial infarction, stroke, and graft
cclusion) between the placebo and treatment groups did
ot reach statistical significance. The study was underpow-
red to determine the safety of factor VIIa.
COMMENT. Although the negative impact of perioperative
transfusion on mortality after cardiac surgery is well recog-
nized, the association between pre-operative anemia and
survival after cardiac surgery is less well characterized. The
current findings may reflect chronic or occult morbidity not
accounted for in the risk model, as well as the reduced
ability of anemic patients to compensate for perioperative
blood loss and consequent tissue hypoxia. It is not certainwhether the anemia is itself a cause of excess mortality (and
therefore potentially reversible by pre-operative hematinics
or blood transfusions) or a surrogate for severity of disease or
comorbidity. A larger randomized study powered to detect
a difference in major adverse clinical events would be
required to demonstrate the safety of factor VIIa in the
management of post-operative bleeding.
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